JACOB MATSIL: Open Payments
NPI 1427537521 · ARLINGTON HEIGHTS, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$617 in 34 payments from 15 companies in 2025. Trend: 2023 $70 · 2024 $192 · 2025 $617
Food & beverage: $617
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 12 | $192 |
| Novo Nordisk Inc | 5 | $96 |
| AstraZeneca Pharmaceuticals LP | 3 | $70 |
| GlaxoSmithKline, LLC. | 2 | $46 |
| Lilly USA, LLC | 2 | $37 |
| Esperion Therapeutics, Inc. | 1 | $25 |
| Neurocrine BioSciences, Inc. | 1 | $19 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $18 |
| Exact Sciences Corporation | 1 | $18 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $17 |
Products named: VRAYLAR, QULIPTA, UBRELVY, TRELEGY ELLIPTA, FARXIGA, Ozempic, MOUNJARO, ABILIFY ASIMTUFII.
Industry payments across IL — which companies pay providers there.
